Drug Profile
IMO 2134
Alternative Names: HYB2093; IMO-2134; QAX935Latest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator Idera Pharmaceuticals
- Developer Aceragen
- Class Antineoplastics; Oligonucleotides
- Mechanism of Action Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Asthma; Hypersensitivity